Ameriprise’s Cyclerion Therapeutics CYCN Stock Holding History

Ameriprise’s Portfolio CYCN Stock Details CYCN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-2,241	Closed	-$272K	–	3769
2020 Q3	$272K	Buy	+2,241	New	+$256K	﹤0.01%	3452

Other funds holding CYCN

SPC

Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

MFN Partners Boston, Massachusetts $4.77B AUM 72.29% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Ameriprise's CYCN Position: Q4 2020 in Review

Ameriprise sold out of Cyclerion Therapeutics (CYCN) in Q4 2020, closing a stake of 2,241 shares — an estimated $272K sold.

Ameriprise first reported a position in CYCN in Q3 2020 and held it in 1 quarter. The position peaked at $272K in Q3 2020. 73 funds tracked by Wall St. Rank hold CYCN as of Q4 2020.

Ameriprise reported no remaining Cyclerion Therapeutics position as of Q4 2020 after selling out during the quarter.
Ameriprise sold 2,241 Cyclerion Therapeutics shares in Q4 2020, an estimated $272K.
Ameriprise first reported a position in Cyclerion Therapeutics in Q3 2020 and held it in 1 quarter.
Ameriprise's Cyclerion Therapeutics position peaked at $272K in Q3 2020.
73 funds tracked by Wall St. Rank held Cyclerion Therapeutics as of Q4 2020.

Based on Ameriprise's 13F filing for Q4 2020, filed 12 Feb 2021.